# A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral Dose

> **NCT01663389** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 5 (actual)

## Conditions studied

- Infections, Bacterial

## Interventions

- **DRUG:** GSK1322322 1000 mg containing radioactive 14C-GSK1322322
- **DRUG:** GSK1322322 1200 mg containing radioactive 14C-GSK1322322

## Key facts

- **NCT ID:** NCT01663389
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-10
- **Primary completion:** 2012-10-05
- **Final completion:** 2012-10-05
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2017-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01663389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01663389, "A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral Dose". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01663389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*